Status:
COMPLETED
Comparison of Two NN1250 Formulations in Healthy Volunteers
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This trial was conducted in North America. The aim of this clinical trial was to investigate if two formulations of NN1250 (insulin degludec) have the same level of drug exposure to the body.
Eligibility Criteria
Inclusion
- Considered generally healthy upon completion of medical history, physical examination, vital signs and ECG (electrocardiogram), as judged by the Investigator
- Body mass index 18.0-27.0 kg/m\^2 (both inclusive)
Exclusion
- Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
- Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
- Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00966368
Start Date
August 1 2009
End Date
October 1 2009
Last Update
September 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Clinical Trial Call Center
Chula Vista, California, United States, 91911-1350